General
Preferred name
TEDUGLUTIDE
Synonyms
Gattex ()
ALX-0600, Gattex, Revestive, TAK 633 ()
Teduglutide Recombinant ()
Gattex Kit ()
Revestive ()
Teduglutide (rdna origin) ()
ALX-0600 ()
ALX 0600 ()
P&D ID
PD071711
CAS
197922-42-2
Tags
available
drug
Approved by
PMDA
EMA
FDA
First approval
2012
Drug indication
Short bowel syndrome
Drug Status
approved
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue in which position 2 amino acid alanine is replaced by glycine, increasing the peptide's resistance to proteolytic cleavage by dipeptidyl peptidase-4 (DPP-4) . The chemical structure shown here was generated using the SMILES from PubChem CID 16139605. The intestinotrophic effects of GLP-2 (e.g. promotion of intestinal growth, reduced epithelial cell apoptosis and inflammation) has led to the development of GLP-2 analogues like teduglutide for the treatment of GI disorders such as short bowel syndrome and inflammatory bowel diseases. (GtoPdb)
Compound Sets
9
ChEMBL Approved Drugs
CHEMBL2104987
ChEMBL Drugs
CHEMBL2104987
DrugCentral
4718
DrugCentral Approved Drugs
4718
DrugMAP
DMYOAKS
DrugMAP Approved Drugs
DMYOAKS
Guide to Pharmacology
7049
Natural product-based probes and drugs
Selleckchem Bioactive Compound Library
teduglutide
External IDs
20
Properties
(calculated by RDKit )
Molecular Weight
3749.8
Hydrogen Bond Acceptors
53
Hydrogen Bond Donors
55
Rotatable Bonds
125
Ring Count
5
Aromatic Ring Count
5
cLogP
-16.89
TPSA
1624.22
Fraction CSP3
0.59
Chiral centers
38.0
Largest ring
6.0
QED
0.01
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Short Bowel Syndrome
Target
Glucagon Receptor
Source data